TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
21
11
2023
accepted:
19
02
2024
revised:
15
02
2024
pubmed:
15
3
2024
medline:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
MET amplification/mutations are important targetable oncogenic drivers in NSCLC, however, acquired resistance is inevitable and the majority of patients with targetable MET alterations fail to respond to MET tyrosine kinase inhibitors (TKIs). Furthermore, MET amplification is among the most common mediators of TKI resistance. As such, novel therapies to target MET pathway and overcome MET TKI resistance are clearly needed. Here we show that the epithelial-mesenchymal transition (EMT) transcription factor, TWIST1 is a key downstream mediator of HGF/MET induced resistance through suppression of p27 and targeting TWIST1 can overcome resistance. We found that TWIST1 is overexpressed at the time of TKI resistance in multiple MET-dependent TKI acquired resistance PDX models. We have shown for the first time that MET directly stabilized the TWIST protein leading to TKI resistance and that TWIST1 was required for MET-driven lung tumorigenesis as well as could induce MET TKI resistance when overexpressed. TWIST1 mediated MET TKI resistance through suppression of p27 expression and genetic or pharmacologic inhibition of TWIST1 overcame TKI resistance in vitro and in vivo. Our findings suggest that targeting TWIST1 may be an effective therapeutic strategy to overcome resistance in MET-driven NSCLC as well as in other oncogene driven subtypes in which MET amplification is the resistance mechanism.
Identifiants
pubmed: 38485737
doi: 10.1038/s41388-024-02987-5
pii: 10.1038/s41388-024-02987-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Doris Duke Charitable Foundation
ID : 2015097
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA213765
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
pubmed: 35020204
doi: 10.3322/caac.21708
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.
pubmed: 34985916
doi: 10.1200/JCO.21.01626
Drilon A, Cappuzzo F, Ou S-HI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? J Thor Oncol. 2017;12:15–26.
doi: 10.1016/j.jtho.2016.10.014
Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol. 2013;5:a009209.
pubmed: 23818496
pmcid: 3685898
doi: 10.1101/cshperspect.a009209
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours — molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020;17:569–87.
pubmed: 32514147
pmcid: 7478851
doi: 10.1038/s41571-020-0377-z
Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20:298–304.
pubmed: 18836087
doi: 10.1093/annonc/mdn635
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.
pubmed: 17463250
doi: 10.1126/science.1141478
Sequist LV, Han J-Y, Ahn M-J, Cho BC, Yu H, Kim S-W, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373–86.
pubmed: 32027846
doi: 10.1016/S1470-2045(19)30785-5
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33.
pubmed: 27432227
pmcid: 5050111
doi: 10.1158/2159-8290.CD-16-0596
Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020;31:1725–33.
pubmed: 33007380
doi: 10.1016/j.annonc.2020.09.015
Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res. 2020;26:2535–45.
pubmed: 32086345
pmcid: 7269872
doi: 10.1158/1078-0432.CCR-19-3906
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931–43.
pubmed: 32469185
pmcid: 8422679
doi: 10.1056/NEJMoa2004407
Drilon A, Clark JW, Weiss J, Ou SHI, Camidge DR, Solomon BJ, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26:47–51.
pubmed: 31932802
pmcid: 8500676
doi: 10.1038/s41591-019-0716-8
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944–57.
pubmed: 32877583
doi: 10.1056/NEJMoa2002787
Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, et al. Crizotinib in patients With MET-amplified NSCLC. J Thorac Oncol. 2021;16:1017–29.
pubmed: 33676017
doi: 10.1016/j.jtho.2021.02.010
Paik PK, Drilon A, Fan P-D, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discovery. 2015;5:842–9.
pubmed: 25971939
pmcid: 4658654
doi: 10.1158/2159-8290.CD-14-1467
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin Cancer Res. 2020;26:2615–25.
pubmed: 32034073
doi: 10.1158/1078-0432.CCR-19-3608
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, et al. Amplification of wild-type KRAS Imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clin Cancer Res. 2018;24:5963–76.
pubmed: 30072474
pmcid: 6279568
doi: 10.1158/1078-0432.CCR-18-0876
Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, et al. Activation of KRAS mediates resistance to targeted therapy in MET Exon 14-mutant non-small cell lung cancer. Clin Cancer Res. 2019;25:1248–60.
pubmed: 30352902
doi: 10.1158/1078-0432.CCR-18-1640
Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, et al. Acquired METD1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 2016;6:1334–41.
pubmed: 27694386
pmcid: 5140694
doi: 10.1158/2159-8290.CD-16-0686
Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, et al. Sensitivity and resistance of MET Exon 14 mutations in lung cancer to Eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol. 2019;14:1753–65.
pubmed: 31279006
doi: 10.1016/j.jtho.2019.06.023
Clement MS, Gammelgaard KR, Nielsen AL, Sorensen BS. Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells. Transl Lung Cancer Res. 2020;9:1904–14.
pubmed: 33209611
pmcid: 7653150
doi: 10.21037/tlcr-20-522
Rastogi I, Rajanna S, Webb A, Chhabra G, Foster B, Webb B, et al. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun. 2016;477:937–44.
pubmed: 27396618
pmcid: 4967022
doi: 10.1016/j.bbrc.2016.07.003
Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet. 2012;8:e1002650.
pubmed: 22654667
pmcid: 3360067
doi: 10.1371/journal.pgen.1002650
Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, et al. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Mol Cancer Res. 2013;11:329–38.
pubmed: 23364532
pmcid: 3631276
doi: 10.1158/1541-7786.MCR-12-0456
Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, et al. A first-in-class TWIST1 inhibitor with activity in oncogene-driven lung cancer. Mol Cancer Res. 2017;15:1764–76.
pubmed: 28851812
pmcid: 5712248
doi: 10.1158/1541-7786.MCR-17-0298
Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O’Brien JP, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019;38:656–70.
pubmed: 30171258
doi: 10.1038/s41388-018-0482-y
Baschnagel AM, Kaushik S, Durmaz A, Goldstein S, Ong IM, Abel L, et al. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Sci Rep. 2021;11:2520.
pubmed: 33510214
pmcid: 7843608
doi: 10.1038/s41598-021-81832-1
Hulton CH, Costa EA, Shah NS, Quintanal-Villalonga A, Heller G, de Stanchina E, et al. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nat Cancer. 2020;1:359–69.
pubmed: 33345196
pmcid: 7745982
doi: 10.1038/s43018-020-0040-8
Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF. Acquired resistance to the Hsp90 inhibitor, ganetespib in KRAS mutant NSCLC is mediated via reactivation of the ERK-p90RSK-mTOR signaling network. Mol Cancer Ther. 2017;16:793–804.
pubmed: 28167505
pmcid: 5418121
doi: 10.1158/1535-7163.MCT-16-0677
Baltschukat S, Engstler BS, Huang A, Hao HX, Tam A, Wang HQ, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25:3164–75.
pubmed: 30674502
doi: 10.1158/1078-0432.CCR-18-2814
Alburquerque-Bejar JJ, Navajas-Chocarro P, Saigi M, Ferrero-Andres A, Morillas JM, Vilarrubi A, et al. MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. Cell Rep Med. 2023;4:101006.
pubmed: 37044092
pmcid: 10140599
doi: 10.1016/j.xcrm.2023.101006
Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst. 2017;109 https://doi.org/10.1093/jnci/djw262 .
Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS. et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun.2022;13:1894.
pubmed: 35365656
pmcid: 8976007
doi: 10.1038/s41467-022-29467-2
Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M. et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020;11:4527.
pubmed: 32913197
pmcid: 7484793
doi: 10.1038/s41467-020-18372-1
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011;6:1624–31.
pubmed: 21716144
doi: 10.1097/JTO.0b013e31822591e9
Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015;90:369–74.
pubmed: 26791794
doi: 10.1016/j.lungcan.2015.10.028
Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis. 2006;27:1547–55.
pubmed: 16513678
doi: 10.1093/carcin/bgl003
Stabile LP, Kumar V, Gaither-Davis A, Huang EH, Vendetti FP, Devadassan P. et al. Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden. JCI insight. 2021;6:e145307.
pubmed: 33351788
pmcid: 7934870
doi: 10.1172/jci.insight.145307
Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011;6:2011–7.
pubmed: 22052230
doi: 10.1097/JTO.0b013e31823ab0dd
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479–87.
pubmed: 19010923
doi: 10.1158/0008-5472.CAN-08-1643
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Bio. 2003;4:915–25.
doi: 10.1038/nrm1261
Liu F, Song SS, Yi Z, Zhang M, Li JL, Yang F, et al. HGF induces EMT in non-small-cell lung cancer through the hBVR pathway. Eur J Pharmacol. 2017;811:180–90.
pubmed: 28554854
doi: 10.1016/j.ejphar.2017.05.040
Joseph NA, Chiou SH, Lung Z, Yang CL, Lin TY, Chang HW, et al. The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. J Hematol Oncol. 2018;11:74.
pubmed: 29855336
pmcid: 5984410
doi: 10.1186/s13045-018-0557-9
Hong J, Zhou J, Fu J, He T, Qin J, Wang L, et al. Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res. 2011;71:3980–90.
pubmed: 21502402
pmcid: 3107354
doi: 10.1158/0008-5472.CAN-10-2914
Razavipour SF, Harikumar KB, Slingerland JM. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res. 2020;80:3451–8.
pubmed: 32341036
doi: 10.1158/0008-5472.CAN-19-3663
Schuler M, Berardi R, Lim WT, de Jonge M, Bauer TM, Azaro A, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. Ann Oncol. 2020;31:789–97.
pubmed: 32240796
doi: 10.1016/j.annonc.2020.03.293
Recondo G, Che J, Janne PA, Awad MM. Targeting MET dysregulation in cancer. Cancer Discov. 2020;10:922–34.
pubmed: 32532746
pmcid: 7781009
doi: 10.1158/2159-8290.CD-19-1446
Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341–58.
pubmed: 29674709
doi: 10.1038/s41568-018-0002-y
Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, et al. Landscape of acquired resistance to osimertinib in EGFR-Mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discovery. 2018;8:1529–39.
pubmed: 30257958
pmcid: 6279502
doi: 10.1158/2159-8290.CD-18-1022
Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79:689–98.
pubmed: 30718357
doi: 10.1158/0008-5472.CAN-18-1281
Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8:714–29.
pubmed: 29650534
pmcid: 5984716
doi: 10.1158/2159-8290.CD-17-1256
Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res. 2021;27:34–42.
pubmed: 33082208
doi: 10.1158/1078-0432.CCR-20-2278
Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019;25:1422–7.
pubmed: 31406350
pmcid: 6736691
doi: 10.1038/s41591-019-0542-z
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–81.
pubmed: 34096690
pmcid: 9116274
doi: 10.1056/NEJMoa2103695
Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382–93.
pubmed: 34161704
pmcid: 8864540
doi: 10.1056/NEJMoa2105281
Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A, Takeda Y, et al. Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep. 2015;33:391–6.
pubmed: 25338771
doi: 10.3892/or.2014.3560
Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2667–74.
pubmed: 26169611
doi: 10.1200/JCO.2014.60.7317
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 2014;20:4488–98.
pubmed: 24687921
pmcid: 4504679
doi: 10.1158/1078-0432.CCR-13-1836
Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Mocci S, Phan S, et al. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2017;35:412–20.
pubmed: 27937096
doi: 10.1200/JCO.2016.69.2160
Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, et al. First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. Cancer Treat Res Commun. 2019;18:100113.
pubmed: 30472556
doi: 10.1016/j.ctarc.2018.10.004
Wu Y-L, Zhang L, Kim D-W, Liu X, Lee DH, Yang JC-H, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor–dysregulated non–small-cell lung cancer. J Clin Oncol. 2018;36:3101–9.
pubmed: 30156984
doi: 10.1200/JCO.2018.77.7326
Gainor JF, Niederst MJ, Lennerz JK, Dagogo-Jack I, Stevens S, Shaw AT, et al. Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification. J Thorac Oncol. 2016;11:e83–85.
pubmed: 26988570
doi: 10.1016/j.jtho.2016.02.021
Yoshida K, Choisunirachon N, Saito T, Matsumoto K, Saeki K, Mochizuki M, et al. Hepatocyte growth factor-induced up-regulation of Twist drives epithelial-mesenchymal transition in a canine mammary tumour cell line. Res Vet Sci. 2014;97:521–6.
pubmed: 25278141
doi: 10.1016/j.rvsc.2014.09.014
Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov. 2012;2:248–59.
pubmed: 22585995
doi: 10.1158/2159-8290.CD-11-0270
Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852–60.
pubmed: 22751098
pmcid: 3408577
doi: 10.1038/ng.2330
Yochum ZA, Socinski MA, Burns TF. Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance. J Thorac Dis. 2016;8:E1528–E1531.
pubmed: 28066651
pmcid: 5179406
doi: 10.21037/jtd.2016.11.59
Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 2019;366:eaaw2106.
pubmed: 31831640
pmcid: 7592119
doi: 10.1126/science.aaw2106
Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375:eabc1495.
pubmed: 35025636
pmcid: 9048628
doi: 10.1126/science.abc1495
Nagai, Miyazawa Y, Huqun H, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276–82.
pubmed: 16105816
doi: 10.1158/0008-5472.CAN-05-0331
Seki N, Hoshino T, Kikuchi M, Hayashi A, Itoh K. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cell Immunol. 1997;175:101–10.
pubmed: 9023415
doi: 10.1006/cimm.1996.1062
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283–98.
pubmed: 16564017
doi: 10.1016/j.cell.2006.01.040
Bencivenga D, Stampone E, Aulitto A, Tramontano A, Barone C, Negri A, et al. A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function. Mol Oncol. 2021;15:915–41.
pubmed: 33316141
pmcid: 8024736
doi: 10.1002/1878-0261.12881
Kumar V, Chaudhary AK, Dong Y, Zhong HA, Mondal G, Lin F, et al. Design, synthesis and biological evaluation of novel hedgehog inhibitors for treating pancreatic cancer. Sci Rep. 2017;7:1665.
pubmed: 28490735
pmcid: 5431907
doi: 10.1038/s41598-017-01942-7
Kumar V, Kumar V, Chaudhary AK, Coulter DW, McGuire T, Mahato RI. Impact of miRNA-mRNA profiling and their correlation on medulloblastoma tumorigenesis. Mol Ther Nucleic Acids. 2018;12:490–503.
pubmed: 30195786
pmcid: 6070673
doi: 10.1016/j.omtn.2018.06.004